Results 11 to 20 of about 530,938 (302)

New Interleukin-23 Antagonists' Use in Crohn's Disease. [PDF]

Pharmaceuticals (Basel)
Crohn’s disease (CD) is a chronic inflammatory condition of the digestive tract, driven by an imbalance in immune system regulation, where proinflammatory interleukin-23 (IL-23) plays an essential role. Selective new IL-23 inhibitors, including risankizumab, guselkumab, and mirikizumab, block the IL-23p19 subunit to inhibit the Il-23 action and ...
Biskup L, Semeradt J, Rogowska J, Chort W, Durko Ł, Małecka-Wojciesko E.   +5 more
europepmc   +4 more sources

Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries. [PDF]

J Clin Med, 2023
Sisto M, Lisi S.
europepmc   +5 more sources

Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. [PDF]

N Engl J Med
Autoantibodies against interleukin-12 (anti-interleukin-12) are often identified in patients with thymoma, but opportunistic infections develop in only some of these patients. Interleukin-12 (with subunits p40 and p35) shares a common subunit with interleukin-23 (subunits p40 and p19). In a patient with disseminated Burkholderia gladioli infection, the
Cheng A, Kashyap A, Salvator H, Rosen LB, Colby D, Ardeshir-Larijani F, Loehrer PJ, Ding L, Lugo Reyes SO, Riminton S, Ballman M, Rocco JM, Marciano BE, Freeman AF, Browne SK, Hsu AP, Zelazny A, Rajan A, Sereti I, Zerbe CS, Lionakis MS, Holland SM.   +21 more
europepmc   +7 more sources

Interleukin-23 in perspective. [PDF]

Rheumatology (Oxford), 2021
Sherlock JP, Cua DJ.
europepmc   +4 more sources

Epithelial-derived interleukin-23 promotes oral mucosal immunopathology. [PDF]

Immunity
At mucosal surfaces, epithelial cells provide a structural barrier and an immune defense system. However, dysregulated epithelial responses can contribute to disease states. Here, we demonstrated that epithelial cell-intrinsic production of interleukin-23 (IL-23) triggers an inflammatory loop in the prevalent oral disease periodontitis.
Kim TS, Ikeuchi T, Theofilou VI, Williams DW, Greenwell-Wild T, June A, Adade EE, Li L, Abusleme L, Dutzan N, Yuan Y, Brenchley L, Bouladoux N, Sakamachi Y, NIDCD/NIDCR Genomics and Computational Biology Core, Palmer RJ, Iglesias-Bartolome R, Trinchieri G, Garantziotis S, Belkaid Y, Valm AM, Diaz PI, Holland SM, Moutsopoulos NM.   +23 more
europepmc   +3 more sources

Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices. [PDF]

Biologics, 2023
Haroon MM, Hegazy GA, Hassanien MA, Shaker O, Hussein WH.   +4 more
europepmc   +3 more sources

A Genome-Wide Association Study Identifying Novel Genetic Markers of Response to Treatment with Interleukin-23 Inhibitors in Psoriasis. [PDF]

Genes (Basel)
Zachari S, Liadaki K, Planaki A, Zafiriou E, Kouvarou O, Gerogianni K, Giannoulis T, Mamuris Z, Bogdanos DP, Moschonas NK, Sarafidou T.   +10 more
europepmc   +3 more sources

Interleukin 23 in Crohnʼs Disease [PDF]

Inflammatory Bowel Diseases, 2014
: Crohn's disease (CD) is a lifelong inflammatory condition with underlying environmental and genetic components. CD affects multiple parts of the gastrointestinal tract, and it has a growing incidence in Western societies. IL-23 receptor variants have been identified as susceptibility or resistance factors for CD in genome-wide association studies ...
Oukka, Mohamed, Eken, Ahmet, Singh, Akhilesh K.   +2 more
openaire   +3 more sources

Interleukin-23 Inhibitors

TURKDERM, 2022
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis patients being treated with IL-23 inhibitors.
openaire   +3 more sources

Progress in spondylarthritis immunopathogenesis of spondyloarthritis: which cells drive disease? [PDF]

, 2009
Spondyloarthritides, or SpA, form a cluster of chronic inflammatory diseases with the axial skeleton as the most typical disease localisation, although extra-articular manifestations such as intestinal inflammation may frequently occur during the course ...
Melis, Lode, Elewaut, Dirk
core   +2 more sources